Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: A review

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 4 SUPPL. S1, 2000, Pages 35-39

  Hammerschlag, Margaret R ^a,b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b Box 49 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; BETA LACTAM; CEFTRIAXONE; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; SULFAMETHOXAZOLE; TETRACYCLINE; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; BACTERICIDAL ACTIVITY; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; GRAM POSITIVE BACTERIUM; HUMAN; LOWER RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE;

ADULT; ANTI-INFECTIVE AGENTS; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES;

EID: 0034035396     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Grayston, J. T., Campbell, L. A., Kuo, C.-C., Mordhorst, C. H., Saikku, P., Thom, D. H. et al. (1990). A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. Journal of Infectious Diseases 161, 618-25.
2. Hammerschlag, M. R. (1999). Community-acquired pneumonia due to atypical organisms in adults: diagnosis and treatment. Infectious Diseases in Clinical Practice 8, 232-40.
3. Grayston, J. T., Aldous, M. B., Easton, A., Wang, S. P., Kuo, C. C., Campbell, L. A. et al. (1993). Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis. Journal of Infectious Diseases 168, 1231-5.
4. Emre, U., Roblin, P. M., Gelling, M., Dumornay, W., Rao, M., Hammerschlag, M. R. et al. (1994). The association of Chlamydia pneumoniae infection and reactive airway disease in children. Archives of Pediatrics and Adolescent Medicine 148, 727-32.
5. Block, S. L., Hammerschlag, M. R., Hedrick, J., Tyler, R., Smith, A., Roblin, P. et al. (1997). Chlamydia pneumoniae in acute otitis media. Pediatric Infectious Disease Journal 16, 858-62.
6. Hammerschlag, M. R., Chirgwin, K., Roblin, P. M., Gelling, M., Dumornay, W., Mandel, L. et al. (1992). Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clinical Infectious Diseases 14, 178-82.
7. Dean, D., Roblin, P. M., Mandell, L., Schachter, J. & Hammerschlag, M. R. (1998). Molecular evaluation of serial isolates from patients with persistent Chiamydia pneumoniae infections. In Chlamydial Infections. Proceedings of the Ninth International Symposium on Human Chlamydial Infection, University of California, San Francisco (Stephens, R. S., Byrne, G. I., Christiansen, G., Clarke, I. N., Grayston, J. T., Rank, R. G. et al., Eds), pp. 219-23. University of California, San Francisco, CA.
8. Weiss, S. M. & Hammerschlag, M. R. (1997). Are heart attacks infectious? A critical look at the link between Chlamydia pneumoniae and atherosclerosis. Bulletin de l'Institut Pasteur 95, 107-13.
9. Dessus-Babus, S., Bebear, C. M., Charron, A., Bebear, C. & de Barbeyrac, B. (1998). Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained in vitro. Antimicrobial Agents and Chemotherapy 42, 2474-81.
10. Hammerschlag, M. R. (1994). Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy 38, 1873-8.
11. Hammerschlag, M. R., Hyman, C. L. & Roblin, P. M. (1992). In vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy 36, 682-3.
12. Roblin, P. M., Kutlin, A. & Hammerschlag, M. R. (1997). In vitro activity of trovafloxacin against Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy 41, 2033-4.
13. Roblin, P. M. & Hammerschlag, M. R. (1998). In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy 42, 951-2.
14. Hammerschlag, M. R., Qumei, K. K. & Roblin, P. M. (1992). In vitro activities of azithromycin, clarithromycin, L-ofloxacin and other antibiotics against Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy 36, 1573-4.
15. Woodcock, J. M., Andrews, J. M., Boswell, F. J., Brenwald, N. P. & Wise, R. (1997). In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrobial Agents and Chemotherapy 41, 101-6.
16. Ridgway, G. L., Salman, H., Robbins, M. J., Dencer, C. & Felmingham, D. (1997). In-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. Journal of Antimicrobial Chemotherapy 40, Suppl. A, 31-4.
17. Miyashita, N., Niki, Y., Kishimoto, T., Nakajima, M. & Matsushima, T. (1997). In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Antimicrobial Agents and Chemotherapy 41, 1331-4.
18. Kimura, M., Kishimoto, T., Niki, Y. & Soejima, R. (1993). In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents. Antimicrobial Agents and Chemotherapy 37, 801-3.
19. Wise, R., Andrews, J. M. & Brenwald, N. (1993). The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone. Journal of Antimicrobial Chemotherapy 31, 497-504.
20. Roblin, P. M., Montalban, G. & Hammerschlag, M. R. (1994). In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy 38, 1402-3.
21. Roblin, P. M., Kutlin, A., Reznik, T. & Hammerschlag, M. R. (1999). Activity of grepafloxacin and other fluoroquinolones and newer macrolides against recent clinical isolates of Chlamydia pneumoniae. International Journal of Antimicrobial Agents 12, 181-4.
22. Donati, M., Rodriguez Fermepin, M., Olmo, A., D'Apote, L. & Cevinini, R. (1999). Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp. Journal of Antimicrobial Chemotherapy 43, 825-7.
23. Roblin, P. M. & Hammerschlag, M. R. (1999). In vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae. Journal of Antimicrobial Chemotherapy 44, 549-51.
24. Ridgway, G. L., Salman, H., Clark, S., Mathias, I. & Felmingham, D. (1998). SB-265805 (LB20304a): comparative in vitro activity against Legionella pneumophila and Chlamydia spp. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract F-097, p. 256. American Society for Microbiology, Washington, DC.
25. Roblin, P. M., Reznik, T., Kutlin, A. & Hammerschlag, M. R. (1999). In vitro activities of gemifloxacin (SB-265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy 43, 2806-7.
26. Block, S., Hedrick, J., Hammerschlag, M. R., Cassell, G. H. & Craft J. C. (1995). Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs erythromycin ethylsuccinate. Pediatric Infectious Diseases Journal 14, 471-7.
27. Lipsky, B. A., Tack, K. J., Kuo, C. C., Wang, S. P. & Grayston, J. T. (1990). Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections. American Journal of Medicine 89, 722-4.
28. Plouffe, J. F., Herbert, M. T., File, T. M., Baird, I., Parsons, J. N., Kahn, J. B. et al. (1996). Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group. Antimicrobial Agents and Chemotherapy 40, 1175-9.
29. File, T. M., Segreti, J., Dunbar, L., Player, R., Kohler, R., Williams, R. R. et al. (1997). A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrobial Agents and Chemotherapy 41, 1965-72.
30. Leophonte, P., Baldwin, R. J. T. & Pluck, N. (1998). Trovafloxacin versus amoxicillin/clavulanic acid in the treatment of acute exacerbations of chronic obstructive bronchitis. European Journal of Clinical Microbiology and Infectious Diseases 17, 434-40.
31. DeAbate, C. A., Henry, D., Bensch, G., Jubran, A., Chodosh, S., Harper, L. et al. (1998). Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis - a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group. Chest 114, 120-30.
32. Roblin, P. M. & Hammerschlag, M. R. (1998). Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. Antimicrobial Agents and Chemotherapy 42, 194-6.
33. Bartlett, J. G., Breiman, R. F., Mandell, L. A. & File, T. M. (1998). Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clinical Infectious Diseases 26, 811-38.